Despite advances in diagnosis and management, cardiovascular diseases (CVDs) remain 22 the leading cause of death in the US. Atherosclerosis is the most common form of CVD and the 23 vulnerability of atherosclerotic plaques to rupture is a primary determinant for risk of catastrophic 24 ischemic events. Current imaging of atherosclerotic disease focuses on assessing plaque size and 25 the degree of luminal stenosis, which are not good predictors of plaque stability. Functional 26 methods to identify biomarkers of inflammation in plaques could facilitate assessment of plaque 27
Cardiovascular disease is the leading cause of death for both males and females in the United States. [1] In particular, atherosclerosis is responsible for catastrophic manifestations of heart disease such as myocardial infarction and stroke.[2] Recent understanding of the pathophysiology of plaque formation has identified chronic inflammation as a hallmark of plaque development; tomography (CT), can provide structural information, but does not provide physiological 
Characterization of VDIO-DOTA and DIO (control)
VDIO-DOTA (DOTA= 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid; VDIO= 115 VCAM-conjugated DIO;). The physical properties of VDIO-DOTA and its precursor DIO are 116 summarized in Figure 2a . Following the syntheses described, the DIO and VDIO-DOTA iron oxide 117 core sizes were measured to be 7.3 ± 2.9 nm by averaging 500 particle measurements from TEM 118 images as shown in representative images in Figure 2b and 
218
The lower resolution of PET provides decreased accuracy in determining inflamed regions due 219 to partial volume effects, and subtle inflammatory lesions may be missed. This is suggested by the nanoparticle contrast agent to visualize distribution of an early marker of inflammation. We found diagnosis and patient stratification by PET/MRI could provide clinical benefit as drugs to ameliorate plaque vulnerability come available.
In summary, we have demonstrated an approach to identify early inflammatory changes in vessel injury using a targeted multimodal probe coupled with hybrid PET/MRI imaging in vivo.
for 36h. Excess ammonium hydroxide was removed by dialyzing the solution against deionized water for 72h with 8-10 changes of deionized water. 
Conjugation
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The activity of the injected dose was confirmed by measuring the difference in radioactivity 
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To compare the focal NP uptake between time points, dosage and subjects, we calculated a 556 contrast ratio (CR) metric as previously described.
[36] This normalizes particle uptake at the 557 ligation site between subjects and factors out the signal contribution due to blood borne particles by 558 comparison with the contralateral control.
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Briefly, CR is defined as:
fixed in 4% formaldehyde, and then dehydrated by passing tissue through increasing and the melted wax filled the spaces that used to contain water. After cooling, the tissue hardened 
